ArticleNPJ breast cancer2022
The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment.
Article in NPJ breast cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Are There Socio-Demographic Inequalities in the Utilisation of Tumour and ctDNA Somatic Mutation Testing in Solid Tumours? A Systematic Review.Cancer medicine · 2026Pooled it
- Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review.European journal of cancer (Oxford, England : 1990) · 2022Pooled it
- Variation in chemotherapy use across healthcare regions in Sweden and its impact on prognosis in women with HR+/HER2- early breast cancer.Breast cancer research : BCR · 2026Article
- Socioeconomic- and Insurance-Based Inequities in Oncotype DX Testing and Score-Guided Treatment.Cancer medicine · 2025Article
- Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021.NPJ breast cancer · 2025Article
- Article
- Applying a Novel Measure of Community-Level Healthcare Access to Assess Breast Cancer Care Timeliness.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Physician treatment decisions for hormone receptor-positive, HER2-negative early breast cancer in young patients: a Latin American survey.Therapeutic advances in medical oncology · 2025Article
- A latent class assessment of healthcare access factors and disparities in breast cancer care timeliness.PLoS medicine · 2024Article
- How to Tackle Discordance in Adjuvant Chemotherapy Recommendations by Using Oncotype DX Results, in Early-Stage Breast Cancer.Cancers · 2024Article
- Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients.Breast cancer research : BCR · 2024Article
- Adjuvant Chemotherapy in Premenopausal Patients With Hormone-Positive Breast Cancer With a Recurrence Score of 16-25: A Retrospective Analysis Using the National Cancer Database.JCO precision oncology · 2024Article
- Article
- Predicting Chemotherapy Benefit across Different Races in Early-Stage Breast Cancer Patients Using the Oncotype DX Score.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Oncotype DX (ODX) recurrence score (RS) is a validated tool to guide the use of adjuvant chemotherapy (AC) in hormone receptor+/HER2- breast cancer. In this analysis, we examine (1) characteristics associated with ODX testing and (2) the association between ODX RS and receipt of AC across age and nodal status. Women with HR+/HER2-, early-stage (T1-2, N0-1) breast cancers from 2010-2017 in the National Cancer Database were included. 530,125 met inclusion and 255,971 received ODX testing. Older women were less likely to receive testing; however, nodal positivity increased use of testing. High ODX RS was associated with increased mortality, though the association was not consistent across age and was most strongly associated with mortality among younger, node-negative women. Older women with high ODX RS, regardless of nodal status, were less likely to receive AC. Clinicians may be employing ODX RS to support treatment decisions against the receipt of AC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.